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Acute promyelocytic leukemia (APL) is associated with rearrangement of the retinoic acid receptor α (RARα) gene leading 
to the formation of chimeric receptor proteins. In this issue of Cancer Cell, studies by Kwok et al. and Sternsdorf et al. indi-
cate that the ability of the RARα oncoproteins to dimerize/multimerize is an essential feature required for the development 
of disease. Homodimerization allows RARα to bind to corepressors with increased affinity and the ability to bind to novel 
DNA sequences. However, artificial RARα dimers were weak oncogenes in vivo, indicating that the fusion partners confer 
additional properties to RARα to efficiently generate disease.The clinical observation that acute promy-
elocytic leukemia (APL) was uniquely sen-
sitive to all-trans-retinoic acid (ATRA) led 
to the finding that the retinoic acid receptor 
α (RARα) gene was rearranged and fused 
to the PML gene in APL associated with 
t(15;17). Subsequently, four other proteins, 
including PLZF, NPM, NuMA and Stat5b, 
were found as much rarer translocation 
partners. These diverse proteins have at 
least one property in common, the ability to 
self-associate. Two papers in this issue of 
Cancer Cell (Kwok et al., 2006; Sternsdorf 
et al., 2006) represent the latest attempts 
to deconstruct the mode of action of these 
leukemogenic proteins. While dimerization 
indeed is a critical property of the RARα 
fusion oncoproteins, there are a number of 
other characteristics of these proteins that 
collaborate to generate disease.
Only RARα is rearranged in APL
Knockout studies do not indicate an 
essential role for any RAR in myeloid 
development. However, retinoid-deficient 
rodents develop leukopenia, and treat-
ment of their bone marrow ex vivo with 
ATRA increases myeloid colony growth, 
indicating that RAR can modulate myeloid 
development, by regulation of an incom-
pletely identified set of target genes. Why 
is RARα in particular rearranged in every 
case of APL? The answer may lie in the 
inherent repression activity of RARα. 
RARα in the unliganded state strongly 
binds corepressors and binds coactivators 
upon addition of ATRA. By contrast, RARβ 
and RARγ bind corepressors weakly and 
can activate genes even in the absence 
of ATRA (Hauksdottir et al., 2003). 
Overexpression of RARα itself in murine 
marrow yields promyelocytes. The over-
expressed protein might outstrip available 
retinoids in the cell, assume the repres-
sor conformation, and block differentia-
tion. Nevertheless, enforced expression 
of RARα itself has not yielded leukemia 
in mice. Clearly the APL fusion proteins 
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in order to cause disease.
RARα fusion proteins are multimeric
PML and all of the RARα partner proteins 
in APL contain self-association domains, 
which allow the RAR chimeras to bind 
to retinoic acid response elements as a 
dimer in the absence of retinoid X recep-
tor (RXR), as a 1:1 heteromer with RXR, 
and as multimeric complexes. RARα/RXR 
heterodimers bind to direct repeats sepa-
rated by two or five nucleotides, and PML-
RAR homodimers have somewhat altered 
affinity for such sites. Recently, de Thé’s 
group found that PML-RARα/RXR multim-
ers could bind to direct repeats separated 
by as many as 13 nucleotides (Kamashev 
et al., 2004), allowing the oncoprotein to 
bind and potentially regulate an expanded 
repertoire of genes normally not affected 
by RARα (Meani et al., 2005). PML-RARα 
as well as PLZF-RARα can be puri-
fied as high-molecular weight multimers 
(Sternsdorf et al., 2006 and references 
therein) and display decreased ability to 
move within the nucleus, suggesting that 
they might firmly bind to novel or natural 
target genes, potentially occluding bind-
ing of wild-type RARα. The FKBP-RARα 
chimera generated by Kwok et al. (2006) 
formed such high-molecular weight com-
plexes, and disruption of these multimers 
reversed the ability of the fusion protein 
to block differentiation and stimulate self-
renewal of hematopoietic progenitors.
RARα fusion proteins robustly recruit 
corepressors
While RARα/RXR heteromers bind one 
molecule of the SMRT corepressor, PML-
RARα homodimers as well as artificial 
homodimers can bind two SMRT molecules 
(Lin and Evans, 2000), in part explain-
ing why it takes pharmacological doses 
of ATRA to dislodge corepressors from 
PML-RARα. Despite the enhanced ability 
of artificial RARα dimers to bind corepres-er inc.  sors and immortalize a hematopoietic cell 
line, Sternsdorf et al. (2006) showed that 
such proteins are very weakly oncogenic. 
Only 1.5%–3% of a set of transgenic mice 
harboring artificial RARα dimers developed 
myeloproliferation, and few of those mice 
showed a differentiation block. Thus, bona 
fide APL fusion proteins must have addi-
tional functions. This was first evident in 
PLZF, which complexes with several core-
pressors including SMRT, NCoR, and ETO/
MTG8 (Kwok et al., 2006 and references 
therein). Similarly, the PML moiety of PML-
RARα interacts with the Daxx corepressor. 
A mutation that precluded Daxx recruit-
ment but preserved dimerization drastically 
reduced the ability of PML-RARα to block 
hematopoietic differentiation and immor-
talize cells. Fusion of Daxx or a PLZF 
repression domain to such a mutant form 
of PML-RARα rescued its immortaliza-
tion function (Zhu et al., 2005). Kwok et al. 
(2006) take this a step further: a mutation 
in PLZF-RARα that preserved corepres-
sor binding but prohibited multimerization 
could not immortalize hematopoietic cells. 
Immortalization activity was rescued by 
artificial reconstitution of multimerization. 
One interpretation of these results is that 
multimerization of RARα allows firm bind-
ing to novel target genes while the partner 
protein alters the nature repression com-
plex brought to the promoter. Accordingly, 
PML-RARα aberrantly recruits DNA methyl 
transferase and methyl DNA binding pro-
teins to target loci, leading to long-lasting 
gene repression (Di Croce et al., 2002; 
Villa et al., 2006). Lacking partner protein 
sequences, artificial RAR homodimers 
might fail to transform cells because of an 
inability to recruit such a robust repression 
complex to target genes.
RARα is fused to specific partner proteins
The RARα fusion partners have impor-
tant properties aside from their ability to 
dimerize. PML functions in the nucleus 
to organize multiple proteins into large 73
	 p r e v i e w snuclear bodies, modifying proteins such 
as p53 (de Stanchina et al., 2004), and in 
the cytoplasm to affect the TGFβ pathway 
(Lin et al., 2004). PML has tumor growth 
suppressor properties and can be down-
regulated in human cancer. Furthermore, 
Pml null mice have an increased tendency 
to form tumors upon carcinogenic chal-
lenge. Sternsdorf et al. (2006) found that, 
unlike PML-RARα the artificial RARα dim-
ers did not disrupt PML nuclear bodies. 
Furthermore, engineered RARα dimers 
were no more likely to induce myeloid dis-
ease in Pml null mice than in Pml replete 
mice. By contrast, when PML-RARα is 
expressed in PML null marrow, leukemo-
genesis is accelerated (Rego et al., 2001). 
This suggests that another gain of func-
tion of the PML-RARα chimera compared 
to artificial dimeric RARα is its ability to 
be affected by PML-mediated processes. 
The reverse is true as well; PML-RARα 
can affect growth regulation by PML. For 
example, PML facilitates the acetylation 
and stabilization of p53, while PML-RARα 
through its interaction with wild-type PML 
recruits deacetylases to p53, leading to 
its degradation (Insinga et al., 2004). The 
other APL partners also have roles in 
the control of cell proliferation. PLZF is a 
growth suppressor that can repress cyclin 
A2 and c-myc. NPM is essential for genom-
ic stability, NuMA is an essential compo-
nent of the nuclear matrix, and Stat5b is 
a critical gene regulator in cytokine sign-
aling. The ability of the RARα proteins to 
heterodimerize and potentially block the 
activity of their normal counterparts may 
play a role in the increased oncogenicity 
of bona fide APL fusion proteins compared 
to artificial dimers.
RARα fusion proteins activate as well 
as repress transcription
Leukemogenic chimeric repressor pro-
teins can also activate target genes. 
Comparison of the gene expression pat-
terns set by PML-RARα and PLZF-RARα 
in the absence of ATRA revealed the 
repression of a number of myeloid tran-
scriptional regulators, inhibition of genes 
involved in DNA repair and activation of the 
Wnt/Catenin and Jagged/Notch pathways, 
which promote self-renewal of the leuke-
mic cell (Alcalay et al., 2003; Muller-Tidow 
et al., 2004). Gene activation appears to 
be indirect, perhaps due to sequestration 
of corepressors by the fusion proteins. If 
engineered RARα dimers did not have 
sufficient ability to sequester corepressors 
they might fail to fully activate such growth-
promoting genes. This could explain the 
74 reduced ability of an artificial FKBP-RARα 
fusion to stimulate self-renewal of hemat-
opoietic progenitors relative to PLZF-
RARα (Kwok et al., 2006) and the limited 
oncogenicity of artificial dimers in mice 
(Sternsdorf et al., 2006).
RARα fusion proteins collaborate 
with second oncogenic events to 
generate APL
Although the RARα fusion proteins block 
differentiation and promote self-renewal in 
cell lines and cultured murine marrow, they 
cause leukemia in mice only after a long 
latent period, proceeded in one model by 
subtle changes in myeloid differentiation 
and in another by myeloid expansion and 
no differentiation block. Expression profil-
ing of promyelocytes harboring PML-RARα 
from premalignant mice showed that <2% 
of genes had significant changes in expres-
sion compared with normal promyelocytes. 
Only after a latent period of 3–9 months, 
when overt leukemia develops, is a major 
change in gene expression noted (Walter 
et al., 2004). Changes in expression of 
relatively few genes, conceivably ones 
involved in self-renewal and DNA repair, 
might be required to initiate the leukemic 
process, setting up the myeloid progenitor 
for additional mutations that convert the 
disease to frank leukemia. It is clear that 
one such additional hit can be an activat-
ing mutation of a receptor tyrosine kinase 
(RTK) (Sternsdorf et al., 2006 and refer-
ences therein). How does the full differ-
entiation block occur? Given the ability of 
an activated tyrosine kinase to collaborate 
with the artificial RARα dimer, it is possible 
that aberrant signaling can alter the nature 
of the transcription complex recruited to 
RARα. Alternatively, by repressing the 
expression or function of myeloid transcrip-
tion factors, the activated RTK pathways 
may converge with the RARα pathways 
to fully block differentiation and/or activate 
self-renewal.
The papers under consideration show 
that dimerization is an essential quality 
of the APL fusion proteins. Drugs that 
block dimerization, as in the case of the 
FKBP-RARα fusion (Kwok et al., 2006), 
represent another potential therapeutic 
approach for the treatment of APL, par-
ticularly in ATRA-resistant forms associ-
ated with mutations in the ligand binding 
domain of RARα. However, collectively the 
data indicate that the intrinsic ability of the 
RARα partner proteins to recruit repres-
sors and alter gene expression play an 
equally critical role in leukemogenesis.Jonathan D. licht1,*
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